Ozempic (Semaglutide) in Type 1 Diabetes
Ozempic is NOT FDA-approved for type 1 diabetes and should not be routinely used, but emerging evidence suggests it may be considered off-label in select adults with type 1 diabetes who have obesity (BMI ≥30) when used alongside automated insulin delivery systems, with careful monitoring for ketosis. 1
FDA-Approved Indications
The FDA label explicitly states that Ozempic is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. 1 This is a critical limitation that frames all subsequent discussion.
Current Guideline Perspective
The 2025 American Diabetes Association Standards of Care acknowledges that GLP-1 receptor agonists are being studied in type 1 diabetes but emphasizes these agents are "currently approved only for the treatment of type 2 diabetes." 2
Evidence from Clinical Trials:
- Retrospective case series have revealed potential benefits on body weight and glycemic metrics with addition of semaglutide for individuals with type 1 diabetes and obesity. 2
- Prospective studies using semaglutide are ongoing. 2
- The largest trials with liraglutide (another GLP-1 RA) showed modest A1C reductions (0.4%), weight loss (5 kg), and reduced insulin doses, but with concerning findings about beta-cell function deterioration after discontinuation. 2
Recent High-Quality Evidence (2025)
The ADJUST-T1D trial (published in NEJM Evidence, 2025) provides the strongest recent evidence: In 72 adults with type 1 diabetes using automated insulin delivery systems and BMI ≥30, semaglutide up to 1 mg weekly achieved significantly better outcomes than placebo. 3
Key Findings:
- 36% of semaglutide users vs. 0% of placebo users achieved the composite endpoint (time in range >70%, time below range <4%, and ≥5% weight loss). 3
- Mean weight loss was 8.8 kg greater with semaglutide. 3
- A1C decreased by 0.3 percentage points. 3
- Time in range improved by 8.8 percentage points. 3
- Two severe hypoglycemia events occurred in each group, with NO diabetic ketoacidosis reported. 3
A concurrent 2025 Nature Medicine crossover trial confirmed these findings, showing 4.8 percentage point increase in time in range with semaglutide plus automated insulin delivery. 4 However, two episodes of recurrent euglycemic ketosis without acidosis occurred during semaglutide use, highlighting a critical safety concern. 4
Real-World Effectiveness Data
Multiple 2024-2025 retrospective studies demonstrate consistent benefits in clinical practice:
- Weight loss of 9.1% with semaglutide and 21.4% with tirzepatide over 12 months in adults with type 1 diabetes and obesity. 5
- A1C reductions of 0.54% with semaglutide and 0.68% with tirzepatide. 5
- Mean weight loss of 15.9 lbs with 7.9% BMI reduction in another cohort, along with improved CGM metrics (time in range, glucose variability). 6
Critical Safety Considerations
Ketosis Risk:
Unlike SGLT2 inhibitors which carry an eightfold increased DKA risk in type 1 diabetes, semaglutide appears to have a different safety profile. 2 However, euglycemic ketosis without acidosis has been documented. 4
Insulin Dosing Adjustments:
Insulin requirements decrease rapidly upon semaglutide initiation, predominantly affecting bolus insulin due to reduced carbohydrate consumption. 7
- By day 7, total daily insulin and bolus insulin were significantly reduced. 7
- By day 32, basal insulin was significantly reduced. 7
- Carbohydrate ratios increased by median 4.1% and correction factors by 11.2% by day 77. 7
Gastrointestinal Effects:
Nausea and fear of vomiting create barriers to accurate preprandial carbohydrate estimation and bolus dosing. 8 This is particularly problematic in type 1 diabetes where precise carbohydrate counting is essential.
Clinical Algorithm for Consideration
If considering off-label semaglutide in type 1 diabetes, the following criteria should ALL be met:
Patient has BMI ≥30 kg/m² (all published evidence is in this population). 3, 5, 6
Patient is using automated insulin delivery system (evidence strongest in this context). 3, 4
Patient has adequate diabetes self-management skills including carbohydrate counting and ketone monitoring. 7, 8
No personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (absolute contraindication per FDA label). 1
No history of recurrent DKA or severe gastroparesis. 2
Initiation Protocol:
- Start with 0.25 mg weekly for 4 weeks (per FDA dosing for type 2 diabetes). 1
- Reduce total daily insulin by 10-20% at initiation, with particular attention to bolus insulin. 7
- Provide ketone meter and instruct patient to check ketones if feeling unwell, even with normal glucose. 4
- Weekly follow-up during first month to adjust insulin pump parameters (carbohydrate ratios, correction factors, basal rates). 7
- Titrate to 0.5 mg weekly after 4 weeks if tolerated, with further insulin adjustments. 1, 3
- Maximum dose 1 mg weekly (higher doses not studied in type 1 diabetes). 3, 4
Common Pitfalls to Avoid
Do not use semaglutide in type 1 diabetes without automated insulin delivery or continuous glucose monitoring - the evidence base is exclusively in patients using these technologies. 3, 4
Do not assume insulin requirements remain stable - they decline rapidly and require proactive adjustment to prevent hypoglycemia. 7
Do not dismiss gastrointestinal symptoms as benign - they interfere with accurate carbohydrate counting and bolus dosing, which are critical in type 1 diabetes. 8
Do not use in patients unable to monitor ketones - euglycemic ketosis can occur even without the DKA risk seen with SGLT2 inhibitors. 4
Bottom Line
Semaglutide remains off-label and not FDA-approved for type 1 diabetes. 1 However, in carefully selected adults with type 1 diabetes, obesity, and automated insulin delivery systems, semaglutide can provide meaningful improvements in weight, glycemic control, and time in range when used with intensive monitoring and insulin adjustment. 3, 4 The decision requires shared decision-making, acknowledgment of off-label use, and commitment to close follow-up. Prospective safety and efficacy trials are still needed before this can be considered standard practice. 2, 5, 6